Structure via PubChem · Public domain (PubChem)
bromfenac
Sign in to saveAlso known as AHR-10282B, 2-amino-3-(4-bromobenzoyl)benzeneacetic acid, [2-amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) marketed in the US as an ophthalmic solution (brand names Prolensa and Bromday, prior formulation brand name Xibrom, which has since been discontinued) by ISTA Pharmaceuticals for short-term, local use. Prolensa and Bromday are the once-daily formulation of bromfenac, while Xibrom was approved for twice-daily administration. In the European Union, the brand name is Yellox. Bromfenac is indicated for the treatment of ocular inflammation and pain after cataract surgery.
Chemical data
- Formula
- C15H12BrNO3
- Molecular weight
- 334.16 g/mol
- IUPAC name
- 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
- SMILES
- C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O
- InChIKey
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
- XLogP
- 3.3
- Polar surface area
- 80.4 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
Withdrawn- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1997
- Admin. routes
- topical
- Indications
- eye inflammation, inflammation, allergic conjunctivitis, dry eye syndrome
via ChEMBL · EBI
Research
325 papers- Bromfenac.2006
- Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.BMC ophthalmology · 2024
- Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review.Clinical ophthalmology (Auckland, N.Z.) · 2016
- Role of microsomal metabolism in bromfenac-induced cytotoxicity.Chemico-biological interactions · 2024
- Bromfenac Ophthalmic Solution 0.07%: A Review of Its Use After Cataract Surgery.Clinical drug investigation · 2015
via PubMed
Wikidata facts
- Subclass of
- non-steroidal anti-inflammatory drug
- Mass
- 333
- Has use
- medication
Show 7 more facts
- chemical formula
- C₁₅H₁₂BrNO₃
- subject has role
- non-steroidal anti-inflammatory drug
- medical condition treated
- pain
- canonical SMILES
- C1=CC(=C(C(=C1)CC(=O)O)N)C(=O)C2=CC=C(C=C2)Br
- World Health Organisation international non-proprietary name
- bromfenac
- physically interacts with
- Prostaglandin-endoperoxide synthase 2
- Commons category
- Bromfenac
via Wikidata · CC0
~4 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- References
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) marketed in the US as an ophthalmic solution (brand names Prolensa and Bromday, prior formulation brand name Xibrom, which has since been discontinued) by ISTA Pharmaceuticals for short-term, local use. Prolensa and Bromday are the once-daily formulation of bromfenac, while Xibrom was approved for twice-daily administration. In the European Union, the brand name is Yellox. Bromfenac is indicated for the treatment of ocular inflammation and pain after cataract surgery.
== Medical uses ==
Excerpted from Wikipedia’s “bromfenac” article, available under the CC BY-SA 4.0 licence.